Andere Kunden interessierten sich auch für
![Major dietary patterns among patients with type 2 diabetes mellitus]( "Major dietary patterns among patients with type 2 diabetes mellitus")
Major dietary patterns among patients with type 2 diabetes mellitus40,99 €![The Effect of Glibnclamide Versus Metformin]( "The Effect of Glibnclamide Versus Metformin")
The Effect of Glibnclamide Versus Metformin40,99 €![Kinase Inhibitors]( "Kinase Inhibitors")
Kinase Inhibitors29,99 €![The therapeutic strategy for obesity-associated Mets and T2DM]( "The therapeutic strategy for obesity-associated Mets and T2DM")
The therapeutic strategy for obesity-associated Mets and T2DM16,99 €![Mycobacterium specific ATP synthase inhibitors as Anti-tubercular drug]( "Mycobacterium specific ATP synthase inhibitors as Anti-tubercular drug")
Mycobacterium specific ATP synthase inhibitors as Anti-tubercular drug23,99 €![Serum Nitric Oxide and Lipid profile in Type 2 Diabetes Mellitus]( "Serum Nitric Oxide and Lipid profile in Type 2 Diabetes Mellitus")
Serum Nitric Oxide and Lipid profile in Type 2 Diabetes Mellitus46,99 €![Cysteine protease inhibitors as chemotherapy for mice Schistosomiasis]( "Cysteine protease inhibitors as chemotherapy for mice Schistosomiasis")
Cysteine protease inhibitors as chemotherapy for mice Schistosomiasis46,99 €
Diabetes mellitus (DM) is one of the most common chronic disorder with increasing prevalence worldwide. Different classes of oral anti-hyperglycemic agents with nearly equipotent efficacy are now available; however, almost all of them are associated with one or more adverse effects. The new approaches in management of type 2 DM (T2DM) are based upon the effects of incretin hormones; Glucagon-Like Peptide-1 (GLP-1), Glucose-dependent insulinotropic peptide (GIP) and dipeptidyl peptidase (DPP-IV) inhibitors, which act via enhancing the incretin secretion. QSAR is the computer-based mathematical model which establishes a correlation between structure and its biological activity. In present studies, QSAR of one of the reported triazolopiperazine based beta-aminoamides have been studied. In present studies, an attempt was made to synthesize the novel and selective 3-amino-1-(8- (cyclopropyl(3-mercapto-4H-1,2,4-triazol-4-ylamino)methyl)-2-(trifluoromtrifluromethyl)-5,6,7,8-tetrahydro-imidazolo(4,5a)-piperidine.The details of the regressional analysis, QSAR, rationale behind design, synthesis, structural characterisation and DPP- IV enzyme inhibitory activity are presented.